Tissue engineering with adipose-derived stem cells (ADSCs): current and future applications.
Sterodimas A., de Faria J., Nicaretta B., Pitanguy I.
Clinical Trial, published in J Plast Reconstr Aesthet Surg (2009) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- J Plast Reconstr Aesthet Surg (2009)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 19969517
- DOI
- 10.1016/j.bjps.2009.10.028
- Citations
- 173
Abstract (original English)
Soft-tissue loss presents an ongoing challenge in plastic and reconstructive surgery. Standard approaches to soft-tissue reconstruction include autologous tissue flaps, autologous fat transplantation and alloplastic implants. All of these approaches have disadvantages, including donor-site morbidity, implant migration and absorption and foreign body reaction. Stem cell application has recently been suggested as a possible novel therapy. Adipose-derived stem cells (ADSCs) are an abundant, readily available population of multipotent progenitor cells that reside in adipose tissue, which is an easily accessible and abundant source of putative stem cells for translational clinical research. Their therapeutic use in pre-clinical studies and experimental clinical trials has been well documented. We present the current strategies of tissue engineering with ADSC and we discuss the possible future applications of this new method in the field of plastic and reconstructive surgery. Complete understanding of the mechanisms of interactions among adipose stem cells, growth factors and biomaterials in tissue engineering is still lacking. Adipose tissue stem cell-based regenerative strategies hold tremendous promise, although this potential must be balanced against stringent standards of scientific and clinical investigation, before developing 'off-the-shelf' tissue engineering products.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.